Top

BMC Complementary Medicine and Therapies

Published in:

Open Access 01-12-2019 | Dyslipidemia | Research article

A randomized, double blind, placebo controlled, multicenter clinical trial to assess the efficacy and safety of Emblica officinalis extract in patients with dyslipidemia

Authors: Haridas Upadya, S. Prabhu, Aravinda Prasad, Deepa Subramanian, Swati Gupta, Ajay Goel

Published in: BMC Complementary Medicine and Therapies | Issue 1/2019

Abstract

Background

Dyslipidemia is one of the most frequently implicated risk factors for development of atherosclerosis. This study evaluated the efficacy of amla (Emblica officinalis) extract (composed of polyphenols, triterpenoids, oils etc. as found in the fresh wild amla fruit) in patients with dyslipidemia.

Methods

A total of 98 dyslipidemic patients were enrolled and divided into amla and placebo groups. Amla extract (500 mg) or a matching placebo capsule was administered twice daily for 12 weeks to the respective group of patients. The patients were followed up for 12 weeks and efficacy of study medication was assessed by analyzing lipid profile. Other parameters evaluated were apolipoprotein B (Apo B), apolipoprotein A1 (Apo A1), Coenzyme Q10 (CoQ10), high-sensitive C-reactive protein (hsCRP), fasting blood sugar (FBS), homocysteine and thyroid stimulating hormone (TSH).

Results

In 12 weeks, the major lipids such as total cholesterol (TC) (p = 0.0003), triglyceride (TG) (p = 0.0003), low density lipoprotein cholesterol (LDL-C) (p = 0.0064) and very low density lipoprotein cholesterol (VLDL-C) (p = 0.0001) were significantly lower in amla group as compared to placebo group. Additionally, a 39% reduction in atherogenic index of the plasma (AIP) (p = 0.0177) was also noted in amla group. The ratio of Apo B to Apo A1 was reduced more (p = 0.0866) in the amla group as compared to the placebo. There was no significant change in CoQ10 level of amla (p = 0.2942) or placebo groups (p = 0.6744). Although there was a general trend of FBS reduction, the numbers of participants who may be classified as pre-diabetes and diabetes groups (FBS > 100 mg/dl) in the amla group were only 8. These results show that the amla extract used in the study is potentially a hypoglycaemic as well. However, this needs reconfirmation in a larger study.

Conclusions

The Amla extract has shown significant potential in reducing TC and TG levels as well as lipid ratios, AIP and apoB/apo A-I in dyslipidemic persons and thus has scope to treat general as well as diabetic dyslipidemia. A single agent to reduce cholesterol as well as TG is rare. Cholesterol reduction is achieved without concomitant reduction of Co Q10, in contrast to what is observed with statins.

Trial registration

Registered with Clinical Trials Registry- India at www.ctri.nic.in (Registration number: CTRI/2015/04/005682) on 8 April 2015 (retrospectively registered).

Available only for authorised users

Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study Am J Cardiol. 1992;70(7):733–7 PubMed PMID: 1519522.PubMed

Davis NE. Atherosclerosis--an inflammatory process. J Insur Med. 2005;37(1):72–5 PubMed PMID: 15895704.PubMed

Dobiásová M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clin Biochem. 2001;34(7):583–8 PubMed PMID: 11738396.CrossRef

Zhu XW, Deng FY, Lei SF. Meta-analysis of Atherogenic index of plasma and other lipid parameters in relation to risk of type 2 diabetes mellitus. Prim Care Diabetes. 2015;9(1):60–7. https://doi.org/10.1016/j.pcd.2014.03.007 PubMed PMID: 24810146.CrossRefPubMed

Beisiegel U. Lipoprotein metabolism. Eur Heart J. 1998;19(Suppl A):A20–3 PubMed PMID: 9519338.PubMed

Frank PG, Marcel YL. Apolipoprotein A-I: structure-function relationships. J Lipid Res. 2000;41(6):853–72 PubMed PMID: 10828078.PubMed

Packard CJ, Shepherd J. Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol. 1997;17(12):3542–56 PubMed PMID: 9437204.CrossRef

Rifai N, Chapman JF, Silverman LM, Gwynnes JT. Review of serum lipids and apolipoproteins in risk-assessment of coronary heart disease. Ann Clin Lab Sci. 1988;18(6):429–39 PubMed PMID: 3071240.PubMed

Zambon A, Brown BG, Deeb SS, Brunzell JD. Genetics of apolipoprotein B and apolipoprotein AI and premature coronary artery disease. J Intern Med. 2006;259(5):473–80. https://doi.org/10.1111/j.1365-2796.2006.01645.x PubMed PMID: 16629853.CrossRefPubMed

10.

Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 2001;358(9298):2026–33. https://doi.org/10.1016/S0140-6736(01)07098-2 PubMed PMID: 11755609.CrossRefPubMed

11.

Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937–52. https://doi.org/10.1016/S0140-6736(04)17018-9 PubMed PMID: 15364185.CrossRef

12.

Vaessen SF, Schaap FG, Kuivenhoven JA, Groen AK, Hutten BA, Boekholdt SM, et al. Apolipoprotein A-V, triglycerides and risk of coronary artery disease: the prospective Epic-Norfolk population study. J Lipid Res. 2006;47(9):2064–70. https://doi.org/10.1194/jlr.M600233-JLR200 PubMed PMID: 16769999.CrossRefPubMed

13.

Dunder K, Lind L, Zethelius B, Berglund L, Lithell H. Evaluation of a scoring scheme, including proinsulin and the apolipoprotein B/apolipoprotein A1 ratio, for the risk of acute coronary events in middle-aged men: Uppsala longitudinal study of adult men (ULSAM). Am Heart J. 2004;148(4):596–601. https://doi.org/10.1016/j.ahj.2004.03.021 PubMed PMID: 15459588.CrossRefPubMed

14.

Meisinger C, Loewel H, Mraz W, Koenig W. Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study. Eur Heart J. 2005;26(3):271–8. https://doi.org/10.1093/eurheartj/ehi003 PubMed PMID: 15618061.CrossRefPubMed

15.

Sierra-Johnson J, Romero-Corral A, Somers VK, Lopez-Jimenez F, Walldius G, Hamsten A, et al. ApoB/apoA-I ratio: an independent predictor of insulin resistance in US non-diabetic subjects. Eur Heart J. 2007;28(21):2637–43. https://doi.org/10.1093/eurheartj/ehm360 PubMed PMID: 17766927.CrossRefPubMed

16.

Thompson A, Danesh J. Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies. J Intern Med. 2006;259(5):481–92. https://doi.org/10.1111/j.1365-2796.2006.01644.x PubMed PMID: 16629854.CrossRefPubMed

17.

Sniderman AD, Jungner I, Holme I, Aastveit A, Walldius G. Errors that result from using the TC/HDL C ratio rather than the apoB/apoA-I ratio to identify the lipoprotein-related risk of vascular disease. J Intern Med. 2006;259(5):455–61. https://doi.org/10.1111/j.1365-2796.2006.01649.x PubMed PMID: 16629851.CrossRefPubMed

18.

Ginsburg GS, Safran C, Pasternak RC. Frequency of low serum high-density lipoprotein cholesterol levels in hospitalized patients with "desirable" total cholesterol levels. Am J Cardiol. 1991;68(2):187–92 PubMed PMID: 2063780.CrossRef

19.

van Lennep JE, Westerveld HT, van Lennep HW, Zwinderman AH, Erkelens DW, van der Wall EE. Apolipoprotein concentrations during treatment and recurrent coronary artery disease events. Arterioscler Thromb Vasc Biol. 2000;20(11):2408–13 PubMed PMID: 11073845.CrossRef

20.

Sniderman AD, Pedersen T, Kjekshus J. Putting low-density lipoproteins at center stage in atherogenesis. Am J Cardiol. 1997;79(1):64–7 PubMed PMID: 9024738.CrossRef

21.

Carnevale Schianca GP, Pedrazzoli R, Onolfo S, Colli E, Cornetti E, Bergamasco L, et al. ApoB/apoA-I ratio is better than LDL-C in detecting cardiovascular risk. Nutr Metab Cardiovasc Dis. 2011;21(6):406–11. https://doi.org/10.1016/j.numecd.2009.11.002 PubMed PMID: 20171854.CrossRefPubMed

22.

Mathur R, Sharma A, Dixit VP, Varma M. Hypolipidaemic effect of fruit juice of Emblica officinalis in cholesterol-fed rabbits. J Ethnopharmacol. 1996;50(2):61–8 PubMed PMID: 8866725.CrossRef

23.

Jacob A, Pandey M, Kapoor S, Saroja R. Effect of the Indian gooseberry (amla) on serum cholesterol levels in men aged 35-55 years. Eur J Clin Nutr. 1988;42(11):939–44 PubMed PMID: 3250870.PubMed

24.

Anila L, Vijayalakshmi NR. Flavonoids from Emblica officinalis and Mangifera indica-effectiveness for dyslipidemia. J Ethnopharmacol. 2002;79(1):81–7 PubMed PMID: 11744299.CrossRef

25.

Antony B, Merina B, Sheeba V, Mukkadan J. Effect of standardized Amla extract on atherosclerosis and dyslipidemia. Indian J Pharm Sci. 2006;68:437–41.CrossRef

26.

Mishra M, Pathak UN, Khan AB. Emblica officinalis Gaertn and serum cholesterol level in experimental rabbits. Br J Exp Pathol. 1981;62:526–8.PubMedPubMedCentral

27.

Thakur CP, Mandal K. Effect of Emblica officinalis on cholesterol-induced atherosclerosis in rabbits. Ind J Med Res. 1984;79:142–6.

28.

Antony B, Benny M, Kaimal TN. A pilot clinical study to evaluate the effect of Emblica officinalis extract (Amlamax) on markers of systemic inflammation and dyslipidemia. Indian J Clin Biochem. 2008;23(4):378–81. https://doi.org/10.1007/s12291-008-0083-6 PubMed PMID: 23105791; PubMed Central PMCID: PMCPMC3453138.CrossRefPubMedPubMedCentral

29.

Antony B, Merina B, Sheeba V. Amlamax in the management of dyslipidemia in humans. Indian J Pharm Sci. 2008;70(4):504–7. https://doi.org/10.4103/0250-474X.44604 PubMed PMID: 20046781; PubMed Central PMCID: PMCPMC2792547.CrossRefPubMedPubMedCentral

30.

Gopa B, Bhatt J, Hemavathi KG. A comparative clinical study of hypolipidemic efficacy of Amla (Emblica officinalis) with 3-hydroxy-3-methylglutaryl-coenzyme-a reductase inhibitor simvastatin. Indian J Pharmacol. 2012;44(2):238–42. https://doi.org/10.4103/0253-7613.93857 PubMed PMID: 22529483; PubMed Central PMCID: PMCPMC3326920.CrossRefPubMedPubMedCentral

31.

Muthayya S, Sugimoto JD, Montgomery S, Maberly GF. An overview of global rice production, supply, trade, and consumption. Ann N Y Acad Sci. 2014;1324:7–14 PubMed PMID: 25224455.CrossRef

32.

Ray M, Ghosh K, Singh S, Mondal KC. Folk to functional: an explorative overview of rice-based fermented foods and beverages in India. J Ethnic Foods. 2016;3(1):5–18.CrossRef

33.

Cicero AFG, Derosa G. Rice bran and its main components: potential role in the management of coronary risk factors. Curr Top Nutraceutical Res. 2005;3:29–46.

34.

Borresen EC, Jenkins-Puccetti N, Schmitz K, Brown DG, Pollack A, Fairbanks A. A pilot randomized controlled clinical trial to assess tolerance and efficacy of navy bean and Rice bran supplementation for lowering cholesterol in children. Glob Pediatr Health. 2017;16, 4. https://doi.org/10.1177/2333794X17694231 PubMed PMID: 28345013.

35.

Dobiasova M. Atherogenic index of plasma [log(triglycerides/HDL-cholesterol)]: theoretical and practical implications. Clin Chem. 2004;50(7):1113–5. https://doi.org/10.1373/clinchem.2004.033175 PubMed PMID: 15229146.CrossRefPubMed

36.

Havel RJ. Remnant lipoproteins as therapeutic targets. Curr Opin Lipidol. 2000;11(6):615–20 PubMed PMID: 11086335.CrossRef

37.

Fontbonne A, Eschwège E. Insulin-resistance, hypertriglyceridaemia and cardiovascular risk: the Paris prospective study. Diabete Metab. 1991;17(1 Pt 2):93–5 PubMed PMID: 1936489.PubMed

38.

Joseph JP, Afonso M, Berdai D, Salles N, Benard A, Gay B, et al. Benefits and risks for primary prevention with statins in the elderly. Presse Med. 2015;44(12 Pt 1):1219–25. https://doi.org/10.1016/j.lpm.2015.09.015 PubMed PMID: 26585744.CrossRefPubMed

39.

Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–207. https://doi.org/10.1056/NEJMoa0807646 PubMed PMID: 18997196.CrossRefPubMed

40.

Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735–42. https://doi.org/10.1016/S0140-6736(09)61965-6 PubMed PMID: 20167359.CrossRefPubMed

41.

Wang KL, Liu CJ, Chao TF, Huang CM, Wu CH, Chen SJ, et al. Statins, risk of diabetes, and implications on outcomes in the general population. J Am Coll Cardiol. 2012;60(14):1231–8. https://doi.org/10.1016/j.jacc.2012.05.019 PubMed PMID: 22884288.CrossRefPubMed

42.

Waters DD, Ho JE, DeMicco DA, Breazna A, Arsenault BJ, Wun CC, et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J Am Coll Cardiol. 2011;57(14):1535–45. https://doi.org/10.1016/j.jacc.2010.10.047 PubMed PMID: 21453832.CrossRefPubMed

43.

US Food and Drug Administration. FDA drug safety communication: important safety label changes to cholesterol lowering statin drugs. www.fda.gov/Drugs/DrugSafety/ucm293101.htm

Title: A randomized, double blind, placebo controlled, multicenter clinical trial to assess the efficacy and safety of Emblica officinalis extract in patients with dyslipidemia
Authors: Haridas Upadya
S. Prabhu
Aravinda Prasad
Deepa Subramanian
Swati Gupta
Ajay Goel
Publication date: 01-12-2019
Publisher: BioMed Central
Keyword: Dyslipidemia
Published in: BMC Complementary Medicine and Therapies / Issue 1/2019
Electronic ISSN: 2662-7671
DOI: https://doi.org/10.1186/s12906-019-2430-y

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

A randomized, double blind, placebo controlled, multicenter clinical trial to assess the efficacy and safety of Emblica officinalis extract in patients with dyslipidemia

Abstract

Background

Methods

Results

Conclusions

Trial registration

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2019

Pharmacokinetics of cucurbitacin B from Trichosanthes cucumerina L. in rats

Infrared-assisted extraction followed by high performance liquid chromatography to determine angoroside C, cinnamic acid, and harpagoside content in Scrophularia ningpoensis

Anti-obesity effect of Yangkyuksanwha-tang in high-fat diet-induced obese mice

Puerarin inhibits the osteoclastogenesis by inhibiting RANKL-dependent and –independent autophagic responses

Effects of combined extracts of Lepidium meyenii and Allium tuberosum Rottl. on erectile dysfunction

Extracts from Sageretia thea reduce cell viability through inducing cyclin D1 proteasomal degradation and HO-1 expression in human colorectal cancer cells